Introduction
Colorectal cancer (CRC) represents the third leading cause of cancer-related death in the US (1) . Recurrent or metastatic colorectal tumors are largely incurable with median overall survival of ~2 years (2) . Conventional chemotherapy for CRC treatment involves combinations of cytotoxic drugs such as 5-fluorouracil (5-FU), oxaliplatin and irinotecan, and has limited efficacy and substantial side effects due to lack of specificity (3) . The development of targeted anticancer agents has significantly improved efficacy of chemotherapy against metastatic CRC (4) . For example, cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is effective as a single agent or in combination with cytotoxic drugs for treatment of metastatic CRC (4) . The inclusion of targeted therapy is expected to move oncology practice towards personalized treatment (5) .
Regorafenib (Stivarga), a multi-kinase inhibitor that targets the Ras/Raf/MEK/ERK pathway, has recently been approved for the treatment of metastatic CRC and gastrointestinal stromal tumors (6, 7) . A variety of clinical trials have also been initiated to use regorafenib to treat other malignancies, including those of lung, esophageal, and liver. Regorafenib inhibits several kinases that are aberrantly activated in tumor cells, including c-Raf, B-Raf, vascular endothelial growth factor receptors (VEGFRs), platelet-derived growth factor receptor (PDGFR), c-Kit, and Tie-2 (8) . The antitumor activity of regorafenib has been demonstrated in a variety of preclinical models, and is associated with suppression of cell proliferation, induction of apoptosis, and inhibition of tumor angiogenesis (8, 9) . However, it is unclear whether any of these effects is essential for the antitumor activity of regorafenib.
Induction of apoptosis in tumor cells has emerged as a key mechanism of targeted therapies (10) . p53-upregulated modulator of apoptosis (PUMA), a BH3-only Bcl-2 family Author Manuscript Published OnlineFirst on April 24, 2014; DOI: 10.1158/1078-0432.CCR- member, functions as a critical regulator of apoptosis in CRC cells (11) . PUMA is transcriptionally activated by p53 and initiates apoptotic response to DNA damage (12) . It can also be induced in a p53-independent manner by a variety of non-genotoxic stimuli, such as the pan-kinase inhibitor UCN-01 (13) , the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib (14) , and tumor necrosis factor-α (TNF-α) (15) . The p53-independent induction of PUMA by these stimuli is mediated by the transcription factor Forkhead Box O3a (FoxO3a), p73, or nuclear factor κB (NF-κB), respectively (13) (14) (15) . Upon its induction, PUMA potently promotes apoptosis in CRC cells by antagonizing antiapoptotic Bcl-2 family members such as Bcl-X L , activating proapoptotic members Bax and Bak, and resulting in mitochondrial dysfunction and caspase activation (16) (17) (18) .
Our previous study revealed that sorafenib, a regorafenib analog approved for treating liver and kidney tumors, induces PUMA-dependent apoptosis (19) . This prompted us to investigate the role of PUMA in mediating the effects of regorafenib against CRC cells. We found that PUMA is induced by regorafenib through the NF-κB pathway and plays a pivotal role in therapeutic response to regorafenib in CRC cells. Our results suggest that PUMA induction is indicative of the therapeutic efficacy of regorafenib, and likely other targeted agents as well.
Materials and Methods
Cell culture and drug treatment. Human CRC cell lines were purchased from American Type 7 (Millipore, Bellerica, MA), cytochrome oxidase subunit IV (Invitrogen), Mcl-1, IκB, cytochrome c, lamin A/C (Santa Cruz Biotechnology, Santa Cruz, CA), β-actin (Sigma), Bim, α-tubulin (EMD Biosciences, Philadelphia, PA), and Bcl-X L (BD Transduction, San Jose, CA).
Apoptosis assays. Nuclear staining with Hoechst 33258 (Invitrogen) was performed as previously described (13) . Annexin V/propidium iodide (PI) staining was performed using annexin-Alexa 488 (Invitrogen) and PI as described (21) . Cytochrome c release was analyzed by cytochrome c Western blotting of mitochondrial and cytosolic fractions isolated by differential centrifugation (17) . Colony formation was assayed by plating the treated cells in 12-well plates at appropriate dilutions, and allowing for cell growth for 10-14 days, followed by crystal violet were from Dharmacon (La Fayette, CO). The siRNA for GSK3β (sc-35527) and VEGFR2 siRNA (sc-29318) were from Santa Cruz Biotechnology. A non-degradable IκBα super repressor mutant (S32/36A; IκBαM) was previously described (15) .
Analysis of NF-κB nuclear translocation. HCT116 cells were pre-treated with BAY11-7082 or transfected with GSK3β siRNA, and then subjected to regorafenib treatment for 3 hours. Nuclear
Research. Luciferase assays. Luciferase reporter constructs containing WT or mutant PUMA promoter sequence in pBV-Luc vector were previously described (13, 23) . To measure reporter activities, cells were transfected with the WT or mutant PUMA reporters along with the transfection control β-galactosidase reporter pCMVβ (Promega, Madison, WI). Luciferase activities were measured as previously described (22) , and normalized to samples similarly transfected but without drug treatment. All reporter experiments were performed in triplicate and repeated three times.
Chromatin immunoprecipitation (ChIP).
ChIP with p65 antibody (Santa Cruz) was performed using the Chromatin Immunoprecipitation Assay Kit (Millipore) as previously described (20) .
The precipitates were analyzed by PCR using primers 5'-GTCGGTCTGTGTACGCATCG-3' and 5'-CCCGCGTGACGCTACGGCCC-3' to amplify a PUMA promoter fragment containing putative κB sites.
Animal tumor experiments.
All animal experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee. Female 5-6 week-old Nu/Nu mice (Charles River, Wilmington, MA) were housed in a sterile environment with micro isolator cages and allowed access to water and chow ad libitum. Mice were injected subcutaneously in both Statistical Analysis. Statistical analyses were carried out using GraphPad Prism IV software (GraphPad Software, Inc., La Jolla, CA). P-values were calculated using the student's t-test and were considered significant if P <0.05. The means ± one standard deviation (s.d.) were displayed in the figures.
Results

Upregulation of PUMA by regorafenib correlates with apoptosis induction in CRC cells
The recent approval of regorafenib for CRC treatment prompted us to investigate its mechanisms of action in CRC cells (7 (Fig. 1, A and B) . The peaks of PUMA protein and mRNA induction were detected at 24 hours following 40 μmol/L regorafenib treatment (Fig. 1B) . Regorafenib also induced PUMA protein and mRNA expression in p53-KO HCT116 cells (Fig. 1, A-C) . In contrast, regorafenib treatment did not upregulate other proapoptotic Bcl-2 family members, including Bim, Bid and Bak, but reduced the expression of the antiapoptotic proteins Bcl-X L and
Mcl-1 (Fig. 1E) . PUMA was also induced by regorafenib in other CRC cell lines, including p53-WT Lim2405, LoVo, Lim1215, SW48, and RKO cells, and p53-mutant SW837, SW1463, SW480, Vaco432, Vaco400, DLD1, and HT29 cells (Fig. 1E) . Analysis of 13 CRC cell lines revealed a correlation between the induction of PUMA and apoptosis by regorafenib ( Fig. 1E and 1F). Following regorafenib treatment, cell lines with low endogenous expression but strong induction of PUMA had relatively high levels apoptosis, while those with low or no PUMA induction, such as SW837, Lim1215 and SW1463, had low or barely detectable levels of apoptosis, with the exception of Lim2045 (Fig. 1F) . These results suggest that selective induction of PUMA by regorafenib contributes to apoptosis induction in CRC cells.
Regorafenib is dependent on PUMA to induce apoptosis in CRC cells
We then investigated the role of PUMA in regorafenib-induced apoptosis using isogenic HCT116 cell lines. Apoptosis induced by 10-40 μmol/L regorafenib was significantly reduced in PUMA-KO cells, but unaffected in p53-KO cells in comparison with WT HCT116 cells ( Fig.   2A ). Annexin V/PI staining confirmed the reduction of regorafenib-induced apoptosis in PUMA-KO cells (Fig. 2B) . PUMA-dependent apoptotic response to regorafenib was also observed in DLD1 and mouse embryonic fibroblast (MEF) cells (Fig. 2C) Fig. 2D) , mitochondrial membrane permeabilization (Fig. 2E) , and cytochrome c release (Fig. 2F) . Furthermore, PUMA-KO cells had improved long-term survival compared to WT HCT116 cells following regorafenib treatment (Fig. 2G) . Therefore, PUMA is necessary for the apoptotic effect of regorafenib in CRC cells.
PUMA activation by regorafenib is mediated by NF-κB
We then analyzed the mechanism of p53-independent PUMA induction by regorafenib in PUMA upregulation in p53-deficient cells were examined (11). FoxO3a is not involved due to unchanged inhibitory phosphorylation following regorafenib treatment ( Fig. S1C ) (26) , and lack of an effect of FoxO3a knockdown on PUMA induction (Fig. S1D ). p73, a p53 family member (23) , and STAT1, which mediates the effects of sorafenib in pancreatic cancer cells (27) , were also ruled out due to lack of induction or a change in phosphorylation (Fig. S1C ).
The p65 subunit of NF-κB was recently identified as a transcriptional activator of PUMA in response to TNF-α or sorafenib treatment (15, 19) . Activation of NF-κB signaling is characterized by phosphorylation of p65 on several residues and its subsequent translocation to the nucleus, where it activates transcription of target genes (28) . We found that regorafenib treatment induced phosphorylation of S536, the major regulatory site of p65 (29) , in a time-and dosage-dependent manner in HCT116 cells ( Fig. 3B and S2A ). Phosphorylation of S276, another site associated with p65 activation (29) , was also increased after regorafenib treatment, while that of the controversial S468 site was not detected ( siRNA abrogated PUMA induction by regorafenib in both WT and p53-KO HCT116 cells ( Fig.   3C ), as well as in DLD1 cells (Fig. S2C ). The induction of PUMA and apoptosis by regorafenib was also suppressed in p65-KO MEFs ( Fig. 2C and S2D ). Furthermore, regorafenib treatment led to nuclear translocation of p65 as detected by immunofluorescence (Fig. 3D ) and western blot (Fig. 3E, left) . Regorafenib treatment did not activate the previously identified NF-κB responsive element that is responsive to TNF-α treatment (15) , in the distal PUMA promoter region (Frag D, Fig. S2E ).
In contrast, regorafenib treatment strongly activated the proximal 495-bp region of the PUMA promoter (Frag A, Fig. S2E ). Analysis of the DNA sequence in this region identified at least 5 κB sites (Fig. S2F) (19) . The effect of regorafenib treatment on the PUMA promoter was completely blocked only when all 5 κB sites were mutated ( Fig. 3F and S2F ), suggesting that all 5 κB sites contribute to PUMA induction by regorafenib. Furthermore, p65 was found to be recruited to the PUMA promoter containing the κB sites following regorafenib treatment by chromatin immunoprecipitation (ChIP) (Fig. 3G ). These results indicate that p65 directly binds to multiple κB sites in the proximal PUMA promoter region to drive its transcriptional activation in response to regorafenib treatment.
GSK3β-dependent, but IκB-independent p65 activation mediates PUMA induction by regorafenib
The canonical pathway of p65 activation is mediated by IκB phosphorylation and degradation (28) . However, IκB phosphorylation or degradation was unaffected by regorafenib treatment (Fig. S2G ). Transfecting cells with IκBαM, a non-degradable mutant of IκB (15), also did not affect regorafenib-induced PUMA expression (Fig. 4A) , suggesting that the canonical NF-κB pathway is not involved in p65 activation or PUMA induction by regorafenib. Further analysis of other kinases known to activate NF-κB revealed that GSK3β is involved in regorafenib-induced p65 activation. Knockdown of GSK3β by siRNA suppressed regorafenibinduced p65 nuclear translocation (Fig. 4B) , as well as PUMA expression in both HCT116 and RKO colon cancer cells (Fig. 4C) . Furthermore, regorafenib treatment suppressed Ser9 phosphorylation of GSK3β, which inhibits its kinase activity (30) , in both WT and p53-KO HCT116 cells (Fig. 4D) . It has been shown that the ERK kinase can prime the inhibitory GSK3β Ser9 phosphorylation (31). We found that regorafenib treatment strongly suppressed phosphorylation of ERK1/2 (T202/Y204) (Fig. 4E) . Treatment of the ERK inhibitor PD98059 phenocopied regorafenib treatment in blocking GSK3β Ser9 phosphorylation, and promoting p65 phosphorylation, PUMA expression and apoptosis induction ( Fig. 4F and 4G ), suggesting that ERK inhibition mediates the activation of GSK3β, p65 and PUMA by regorafenib. MEK inhibitors were also shown to suppress in vivo growth of CRC cells including HCT116 cells (32) .
Together, these results demonstrate that PUMA induction by regorafenib is mediated by ERK inhibition, relief of GSK3β inhibition, and subsequent p65 activation. 
PUMA is necessary for the in vivo antitumor and antiangiogenic activities of regorafenib
Regorafenib suppresses growth of CRC xenograft tumors effectively (8, 9) . To determine if PUMA mediates tumor suppression by regorafenib, WT and PUMA-KO HCT116 cells were injected subcutaneously into nude mice to establish xenograft tumors. Mice were then treated with 30 mg/kg regorafenib or the control vehicle by oral gavage for 10 consecutive days, as previously described (8, 9) . WT and PUMA-KO tumors were not significantly different in growth in the control group (Fig. 5, A and B ). In line with previous studies (8, 9) , regorafenib treatment suppressed the growth of WT tumors by 70-90% (Fig. 5A ). In contrast, PUMA-KO tumors were significantly less sensitive to regorafenib treatment compared to WT tumors ( Consistent with observations from cultured cells, p65 phosphorylation and PUMA expression were markedly increased in regorafenib-treated xenograft tumors (Fig. 5C ). TUNEL staining revealed significant apoptosis induction in WT tumor tissues from the regorafenib-treated mice, but not the control mice. In contrast, apoptosis was largely reduced in the PUMA-KO tumors (Fig. 5D ). Active caspase 3 staining confirmed regorafenib-induced and PUMA-dependent apoptosis in tumors (Fig. 5E) . Analysis of tumor vasculature by CD31 staining showed that the antiangiogenic effect of regorafenib was reduced in the PUMA-KO tumors (Fig. 5F ).
Suppression of tumor hypoxia, analyzed by Carbonic Anhydrase 9 (CA9) staining, by regorafenib was also decreased in the PUMA-KO tumors compared to WT tumors (Fig. 5G) .
Therefore, the antitumor, apoptotic and antiangiogenic activities of regorafenib in vivo are largely dependent on PUMA.
PUMA mediates the chemosensitization effects of regorafenib
Research. 
Regorafenib has been used in combination with other chemotherapeutic agents for CRC treatment (33) . It is possible that the chemosensitization effects of regorafenib are mediated by simultaneous PUMA induction by regorafenib and other agents through different pathways. We found that regorafenib combined with 5-FU, oxaliplatin, or cisplatin induced higher levels of PUMA, compared to single agent alone (Fig. 6A, 6B and S3A ). This is consistent with concurrent PUMA induction through both p53-dependent and -independent mechanism by DNA damage and regorafenib, respectively. Accordingly, the level of apoptosis was also significantly enhanced in WT HCT116 cells, but not in PUMA-KO cells following the combination treatment (Fig. 6A, 6B and S3B) . Similarly, regorafenib combined with cetuximab, which induces PUMA through p73 via AKT inhibition (14) , enhanced PUMA and apoptosis induction relative to regorafenib or cetuximab alone, and the enhanced apoptosis was PUMA-dependent (Fig. 6C) .
The PUMA-dependent sensitization effect was also observed in cells treated with regorafenib combined with the EGFR TKI gefitinib (Fig. S3C) , or the broad-range kinase inhibitor UCN01 (Fig. S3D ).
To determine if PUMA mediates chemosensitization by regorafenib in vivo, nude mice with WT and PUMA-KO HCT116 xenograft tumors were treated with 15 mg/kg regorafenib, 25 mg/kg 5-FU, or their combination. The combination treatment more effectively suppressed the growth of WT tumors, compared to either regorafenib or 5-FU alone (Fig. 6D) . However, the enhanced tumor suppression by the combination treatment was largely abolished in the PUMA-KO tumors (Fig. 6D and S4A) , which was also associated with decreased apoptosis detected by TUNEL staining (Fig. 6E and S4B) , and active caspase 3 staining (Fig. 6F and S4C in vivo, and manipulating PUMA-mediated apoptosis can improve the therapeutic efficacy of regorafenib.
Discussion
The Ras/Raf/MEK/ERK pathway is aberrantly activated in a large fraction of colorectal tumors due to Ras and Raf mutations (34) . Regorafenib is the first small molecule inhibitor of this pathway that has been approved by the Food and Drug Administration (FDA) for the treatment of metastatic CRC. Regorafenib differs from its analog sorafenib by single fluorine, which leads to a similar, yet distinct biochemical profile compared with sorafenib (24, 35) .
Although sorafenib has been extensively characterized, little is known about how regorafenib inhibits growth of CRC cells. The antiangiogenic activity of regorafenib is thought to largely contribute to its antitumor effects (35) . Our results demonstrate for the first time that tumor suppression by regorafenib is dependent on the cell autonomous process of apoptosis induction, progressing from ERK inhibition, GSK3β activation, and p65 nuclear translocation, leading to PUMA induction and onset of mitochondria-mediated apoptosis. In initial clinical studies, regorafenib appears to be primarily cytostatic, which is unlike many chemotherapeutic drugs or targeted agents that are cytotoxic. Long-lasting tumor stabilization was observed in the majority of treated CRC patients (7). However, retrospective analysis revealed that a subset of treated patients had decreased radiological tumor density as well as cavitation of lung metastases during the course of treatment (36) , which may be related to the pro-apoptotic activity of regorafenib. We performed most in vitro experiments using 40 µmol/L regorafenib to substantially induce PUMA and apoptosis in CRC cells. Importantly, the results of these experiments were confirmed by those from xenograft tumor experiments (Fig. 5 and 6 ). Phase 1 studies showed that the plasma concentrations of regorafenib can reach 5-10 µmol/L in patients (38, 39) . The biologically active concentrations of regorafenib are likely to be higher than those in plasma due to binding to plasma proteins (35) . Colorectal cells may also be topically exposed to orally administrated regorafenib at higher concentrations than those in circulation. Furthermore, regorafenib at a lower dose of 10 µmol/L was sufficient to induce PUMA expression (Fig. 1A ).
These observations suggest that induction of PUMA is likely to be involved in the effects of regorafenib at clinically relevant doses.
PUMA induction plays a role in apoptosis induced by a variety of chemotherapeutic agents, and may be a useful indicator of chemo sensitivity. We previously showed that PUMA induction correlates with differential sensitivity to EGFR TKIs in head and neck cancer cells, and lack of PUMA induction is associated with resistance to EGFR TKIs (14) . Increased PUMA expression was associated with better prognosis in patients receiving 5-FU-based therapy in stage II and III CRC (40) . Furthermore, a recent study demonstrated that response of isolated mitochondria from tumor cells to PUMA Bcl-2 homology 3 (BH3) peptide correlates with chemotherapy response in cancer patients (41) . The results in this study suggest that PUMA induction may be useful as a surrogate biomarker for response of CRC to regorafenib. Although it is often difficult to obtain biopsies from colorectal tumors treated with chemotherapy after surgery, recent studies showed that biomarkers of therapeutic response can be analyzed using circulating tumor DNA (42, 43) , or circulating tumor cells (44) . It might be possible to determine PUMA induction by using such non-invasive approaches.
A number of clinical trials have been initiated to test combinations of regorafenib with conventional cytotoxic agents in CRC patients, such as 5-FU, oxaliplatin and irinotecan (33, 45) .
Our data indicate that enhanced PUMA induction mediates the in vitro and in vivo chemosensitization effects of regorafenib (Fig. 6 ). Regorafenib has also been combined with other targeted agents, such as the anti-VEGF antibody bevacizumab and the anti-EGFR antibodies cetuximab and panitumumab in ongoing clinical trials (33, 45) . Incorporation of regorafenib is expected to sensitize CRC containing the G12 mutations in K-Ras or the V600E mutation in B-Raf, which compromise the effects of EGFR-targeted therapies (46). While regorafenib inhibits ERK and activates p65 to induce PUMA, EGFR inhibitors suppress AKT and induce p73 to activate PUMA (14) . Concurrent PUMA induction through two distinct mechanisms can account for improved therapeutic efficacy of combining regorafenib and EGFR antibodies. In addition, p53-independent and/or -dependent PUMA induction also mediates apoptotic response to other targeted agents, such as the c-MET/ALK inhibitor crizotinib (47), the multi-kinase inhibitor drug sunitinib (48), and the HSP90 inhibitors (49). PUMA induction may serve as a useful indicator of effective drug combinations for developing more efficacious combination regimens with reduced doses and non-overlapping toxicities.
Drug resistance represents a major limitation of chemotherapy, and even more so for targeted therapies. Exploring PUMA-mediated apoptosis can be used to discover more effective anticancer agents to overcome chemo resistance. For this purpose, we have recently developed a high-throughput assay for detecting PUMA induction (unpublished data), which can be used for experiments. ***, P <0.001; **, P <0.01; *, P <0.05. 
